Support from readers like you keeps The Journal open.
You are visiting us because we have something you value. Independent, unbiased news that tells the truth. Advertising revenue goes some way to support our mission, but this year it has not been enough.
If you've seen value in our reporting, please contribute what you can, so we can continue to produce accurate and meaningful journalism. For everyone who needs it.
FOR THE 34-EMPLOYEE company Sprout Pharmaceuticals, August marked the end of long and difficult battle that began when the company was first founded in 2011.
On 18 August, the Food and Drug Administration (FDA) in the United States gave a green light on the company’s sole drug, flibanserin, which comes in the form of a little pink pill designed to spark sexual desire in women suffering from hypoactive sexual desire disorder (HSDD), where they have a chronically low desire to have sex.
And as earlier this week, the drug is available for use in the US, with a prescription.
Business Insider spoke to Sprout Pharmaceuticals CEO Cindy Whitehead back when the drug was approved in August about the obstacles she faced to get this drug approved.
Since Viagra’s approval in 1998, 24 drugs for male sexual dysfunction have been approved. Seventeen years later, women have their first to treat a similar condition.
AP / Press Association Images
AP / Press Association Images / Press Association Images
“It’s breaking up their marriages, it’s really having them feel lesser,” she said of women with hypoactive sexual desire disorder, the condition flibanserin is approved to treat.
I think the possibility of providing women access to a treatment really meant a lot to me.
The disparity from a scientific standpoint makes sense: Men get aroused when blood flows into their genitals. Women don’t respond that easily.
For women, researchers have to look at how to get the brain stimulated to increase sexual desire. But that’s easier said than done.
Pharma giant Boehringer Ingleheim was the first to start developing flibanserin back in 2006, when an antidepressant drug actually increased libido instead of suppressing it, a common side effect for antidepressants.
The FDA rejected the pill in 2010 because it didn’t show a significant change in women’s labedo over placebos. That’s when Whitehead swooped in and snatched it up.
She still thought the drug had the potential to be useful for women with HSDD.
“I saw this spectacular science that was going to be abandoned,” Whitehead said.
And I thought it was going to be abandoned frankly because of a society unwilling to have a frank discussion about sex for women.
It took another rejection from the FDA in 2013 before Sprout could figure out how to meet with the agency’s criteria and move the drug along toward approval, which it finally achieved last week.
“The FDA rules on science,” she said. “And on Tuesday, they ruled on science.”
Advertisement
Just days after FDA approval, Valeant announced its plans to pick up Sprout for $1 billion, with future milestone payments that haven’t been disclosed.
Sprout CEO Cindy Whitehead (centre) and staff.
For Whitehead, an acquisition of her small Sprout team made a lot of sense.
I think what this affords us is to do that in a way that we as a 34-person company wouldn’t have otherwise been able to. I think that means … affordable access for more women.
Whitehead said the acquisition’s been in the works since the FDA panel ruled in favor of Addyi — the market name for flibanserin.
Now that the drug’s approved, Whitehead said the next step is to focus on the short term goals of trying to get it on the market right way.
“I’d love to see this usher in a new era of interest in terms of investment and research for conditions like HSDD that uniquely impact women,” she said.
But there’s still skepticism about how well the drug works, and at what cost. The drug carries some rather serious warnings. And it can cause severe side effects like a drop in blood pressure and fainting when consumed with alcohol.
What’s more, although it was effective in trials in raising the number of times a woman has satisfying sex (which the scientists label “satisfying sexual episodes”), it didn’t improve sexual desire — the very thing the drug was designed to do.
Women in the trials taking flibanserin saw an increase in the number of times they had satisfying sex from roughly 2.8 times a month to an average of 4.5 times a month, an increase of about 1.7 times.
Here’s the problem: Women taking just a placebo in drug trials had more SSEs too, albeit by a slightly smaller number. Women taking a placebo saw their number of SSEs rise from an average of 2.7 per month to 3.7, an increase of 1.
AP / Press Association Images
AP / Press Association Images / Press Association Images
In other words, controlling for the placebo effect, flibanserin’s effectiveness amounted to roughly one extra episode of satisfying sex each month, David Kroll reports in Forbes.
This was most likely one of the reasons the FDA has rejected pharma companies’ petitions for it twice, according to FierceBiotech.
Yet the company making the drug, Sprout Pharmaceuticals, says this is enough of an increase to make it available to women.
And now the FDA appears to have agreed.
“The FDA strives to protect and advance the health of women, and we are committed to supporting the development of safe and effective treatments for female sexual dysfunction,” said Janet Woodcock, M.D., director of the FDA’s Center for Drug Evaluation and Research at the time of Addyi’s approval.
Readers like you are keeping these stories free for everyone...
A mix of advertising and supporting contributions helps keep paywalls away from valuable information like this article.
Over 5,000 readers like you have already stepped up and support us with a monthly payment or a once-off donation.
An Bord Pleanála raised concerns over use of ChatGPT for inspector's report into Limerick plant
Eoghan Dalton
12 hrs ago
17.9k
Gerry Adams
Gerry Adams awarded €100,000 in damages after suing BBC for libel
42 mins ago
6.2k
United Arab Emirates
Kinahan gang figure Sean McGovern lands in Dublin ahead of court appearance
17 hrs ago
53.2k
Your Cookies. Your Choice.
Cookies help provide our news service while also enabling the advertising needed to fund this work.
We categorise cookies as Necessary, Performance (used to analyse the site performance) and Targeting (used to target advertising which helps us keep this service free).
We and our 197 partners store and access personal data, like browsing data or unique identifiers, on your device. Selecting Accept All enables tracking technologies to support the purposes shown under we and our partners process data to provide. If trackers are disabled, some content and ads you see may not be as relevant to you. You can resurface this menu to change your choices or withdraw consent at any time by clicking the Cookie Preferences link on the bottom of the webpage .Your choices will have effect within our Website. For more details, refer to our Privacy Policy.
We and our vendors process data for the following purposes:
Use precise geolocation data. Actively scan device characteristics for identification. Store and/or access information on a device. Personalised advertising and content, advertising and content measurement, audience research and services development.
Cookies Preference Centre
We process your data to deliver content or advertisements and measure the delivery of such content or advertisements to extract insights about our website. We share this information with our partners on the basis of consent. You may exercise your right to consent, based on a specific purpose below or at a partner level in the link under each purpose. Some vendors may process your data based on their legitimate interests, which does not require your consent. You cannot object to tracking technologies placed to ensure security, prevent fraud, fix errors, or deliver and present advertising and content, and precise geolocation data and active scanning of device characteristics for identification may be used to support this purpose. This exception does not apply to targeted advertising. These choices will be signaled to our vendors participating in the Transparency and Consent Framework.
Manage Consent Preferences
Necessary Cookies
Always Active
These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work.
Targeting Cookies
These cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. They do not store directly personal information, but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.
Functional Cookies
These cookies enable the website to provide enhanced functionality and personalisation. They may be set by us or by third party providers whose services we have added to our pages. If you do not allow these cookies then these services may not function properly.
Performance Cookies
These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not be able to monitor our performance.
Store and/or access information on a device 137 partners can use this purpose
Cookies, device or similar online identifiers (e.g. login-based identifiers, randomly assigned identifiers, network based identifiers) together with other information (e.g. browser type and information, language, screen size, supported technologies etc.) can be stored or read on your device to recognise it each time it connects to an app or to a website, for one or several of the purposes presented here.
Personalised advertising and content, advertising and content measurement, audience research and services development 177 partners can use this purpose
Use limited data to select advertising 139 partners can use this purpose
Advertising presented to you on this service can be based on limited data, such as the website or app you are using, your non-precise location, your device type or which content you are (or have been) interacting with (for example, to limit the number of times an ad is presented to you).
Create profiles for personalised advertising 101 partners can use this purpose
Information about your activity on this service (such as forms you submit, content you look at) can be stored and combined with other information about you (for example, information from your previous activity on this service and other websites or apps) or similar users. This is then used to build or improve a profile about you (that might include possible interests and personal aspects). Your profile can be used (also later) to present advertising that appears more relevant based on your possible interests by this and other entities.
Use profiles to select personalised advertising 102 partners can use this purpose
Advertising presented to you on this service can be based on your advertising profiles, which can reflect your activity on this service or other websites or apps (like the forms you submit, content you look at), possible interests and personal aspects.
Create profiles to personalise content 47 partners can use this purpose
Information about your activity on this service (for instance, forms you submit, non-advertising content you look at) can be stored and combined with other information about you (such as your previous activity on this service or other websites or apps) or similar users. This is then used to build or improve a profile about you (which might for example include possible interests and personal aspects). Your profile can be used (also later) to present content that appears more relevant based on your possible interests, such as by adapting the order in which content is shown to you, so that it is even easier for you to find content that matches your interests.
Use profiles to select personalised content 43 partners can use this purpose
Content presented to you on this service can be based on your content personalisation profiles, which can reflect your activity on this or other services (for instance, the forms you submit, content you look at), possible interests and personal aspects. This can for example be used to adapt the order in which content is shown to you, so that it is even easier for you to find (non-advertising) content that matches your interests.
Measure advertising performance 161 partners can use this purpose
Information regarding which advertising is presented to you and how you interact with it can be used to determine how well an advert has worked for you or other users and whether the goals of the advertising were reached. For instance, whether you saw an ad, whether you clicked on it, whether it led you to buy a product or visit a website, etc. This is very helpful to understand the relevance of advertising campaigns.
Measure content performance 73 partners can use this purpose
Information regarding which content is presented to you and how you interact with it can be used to determine whether the (non-advertising) content e.g. reached its intended audience and matched your interests. For instance, whether you read an article, watch a video, listen to a podcast or look at a product description, how long you spent on this service and the web pages you visit etc. This is very helpful to understand the relevance of (non-advertising) content that is shown to you.
Understand audiences through statistics or combinations of data from different sources 96 partners can use this purpose
Reports can be generated based on the combination of data sets (like user profiles, statistics, market research, analytics data) regarding your interactions and those of other users with advertising or (non-advertising) content to identify common characteristics (for instance, to determine which target audiences are more receptive to an ad campaign or to certain contents).
Develop and improve services 102 partners can use this purpose
Information about your activity on this service, such as your interaction with ads or content, can be very helpful to improve products and services and to build new products and services based on user interactions, the type of audience, etc. This specific purpose does not include the development or improvement of user profiles and identifiers.
Use limited data to select content 45 partners can use this purpose
Content presented to you on this service can be based on limited data, such as the website or app you are using, your non-precise location, your device type, or which content you are (or have been) interacting with (for example, to limit the number of times a video or an article is presented to you).
Use precise geolocation data 60 partners can use this special feature
With your acceptance, your precise location (within a radius of less than 500 metres) may be used in support of the purposes explained in this notice.
Actively scan device characteristics for identification 29 partners can use this special feature
With your acceptance, certain characteristics specific to your device might be requested and used to distinguish it from other devices (such as the installed fonts or plugins, the resolution of your screen) in support of the purposes explained in this notice.
Ensure security, prevent and detect fraud, and fix errors 112 partners can use this special purpose
Always Active
Your data can be used to monitor for and prevent unusual and possibly fraudulent activity (for example, regarding advertising, ad clicks by bots), and ensure systems and processes work properly and securely. It can also be used to correct any problems you, the publisher or the advertiser may encounter in the delivery of content and ads and in your interaction with them.
Deliver and present advertising and content 115 partners can use this special purpose
Always Active
Certain information (like an IP address or device capabilities) is used to ensure the technical compatibility of the content or advertising, and to facilitate the transmission of the content or ad to your device.
Match and combine data from other data sources 84 partners can use this feature
Always Active
Information about your activity on this service may be matched and combined with other information relating to you and originating from various sources (for instance your activity on a separate online service, your use of a loyalty card in-store, or your answers to a survey), in support of the purposes explained in this notice.
Link different devices 63 partners can use this feature
Always Active
In support of the purposes explained in this notice, your device might be considered as likely linked to other devices that belong to you or your household (for instance because you are logged in to the same service on both your phone and your computer, or because you may use the same Internet connection on both devices).
Identify devices based on information transmitted automatically 107 partners can use this feature
Always Active
Your device might be distinguished from other devices based on information it automatically sends when accessing the Internet (for instance, the IP address of your Internet connection or the type of browser you are using) in support of the purposes exposed in this notice.
Save and communicate privacy choices 90 partners can use this special purpose
Always Active
The choices you make regarding the purposes and entities listed in this notice are saved and made available to those entities in the form of digital signals (such as a string of characters). This is necessary in order to enable both this service and those entities to respect such choices.
have your say